News & Updates
Filter by Specialty:
First-line camrelizumab-chemo combo boosts OS in advanced squamous NSCLC
Treatment comprising camrelizumab, carboplatin, and paclitaxel in the first-line setting improved overall survival (OS) in patients with advanced squamous non-small-cell lung cancer (NSCLC), according to updated results of the phase III CameL-sq trial from China.
First-line camrelizumab-chemo combo boosts OS in advanced squamous NSCLC
06 May 2022
Oral silymarin reduces chemo-induced hepatotoxicity in breast cancer patients
Administration of oral silymarin leads to a substantial decrease in hepatotoxicity severity after 1 month of treatment in nonmetastatic breast cancer patients on doxorubicin/cyclophosphamide-paclitaxel (AC-T) regimen, reports a study.
Oral silymarin reduces chemo-induced hepatotoxicity in breast cancer patients
06 May 2022
Melflufen for R/R MM: Yay or nay?
In patients with relapsed/refractory multiple myeloma (R/R MM), a combination of melflufen and dexamethasone proved better than an approved doublet standard-of-care (SoC) comprising pomalidomide-dexamethasone in terms of progression-free survival (PFS), the phase III OCEAN trial has shown. However, the overall survival (OS) outcome with the melflufen-containing regimen appeared to digress from the PFS result, potentially casting doubt on its benefit for this condition.
Melflufen for R/R MM: Yay or nay?
06 May 2022
Open surgery a better option than minimally invasive hysterectomy in early cervical cancer?
Undergoing a minimally invasive radical hysterectomy leads to worse survival outcomes compared with open surgery in patients with early cervical cancer, according to final results of the LACC trial presented at SGO 2022.